De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort

American Journal of Hematology
Lapo AlinariKristie A Blum

Abstract

De novo CD5+ diffuse large B-cell lymphomas (DLBCL) are a distinct subgroup of DLBCL with poor prognosis. However the role of rituximab-containing therapy and salvage stem cell transplantation in this patients' population remain to be defined. We retrospectively reviewed clinical features and outcomes of 102 patients with de novo CD5+ DLBCL treated with rituximab-containing therapy at nine different institutions. By Hans' criteria, 64 patients had activated B-cell (ABC) subtype, 24 germinal center B-cell (GCB) subtype, and 14 were not evaluated. No patients had a myc translocation. Eighty-three patients were treated with rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP), 7 with rituximab, etoposide, cyclophosphamide, doxorubicin, vincristine, prednisone (R-EPOCH), and 6 with R-CHOP with methotrexate, 3 g/m(2) . The overall response rate to front-line therapy was 85%. The 3-year progression free survival (PFS) and overall survival (OS) for all patients were 40 and 65%, respectively. The 3-year PFS for ABC- and GCB-subtypes was 34 and 45%, respectively. The 3-year OS for ABC- and GCB-subtypes was 62 and 67%, respectively. The median time to second treatment failure was 3 months and 1 month for ABC- and GC...Continue Reading

References

Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Jun 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laurie H SehnJoseph M Connors
Jun 7, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas M HabermannSandra J Horning
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Mar 16, 2007·Blood·James O Armitage
Jun 25, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D EnnishiK Hatake
Sep 4, 2008·Proceedings of the National Academy of Sciences of the United States of America·Georg LenzLouis M Staudt
Jul 28, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christian GisselbrechtNorbert Schmitz
Jan 5, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K MiyazakiS Nakamura
Sep 29, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Catherine ThieblemontChristian Gisselbrecht
Sep 29, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie M Vose
May 23, 2013·American Journal of Hematology·Preetesh JainSusan O'Brien

❮ Previous
Next ❯

Citations

Jul 18, 2017·Expert Review of Hematology·Alice Di RoccoMaurizio Martelli
Oct 30, 2016·Expert Review of Hematology·Vincent Camus, Hervé Tilly
Jul 9, 2020·Journal of Cutaneous Pathology·Antonio Subtil, Alejandro A Gru
Dec 4, 2016·Hematology·Bertrand Coiffier, Clémentine Sarkozy
Jun 23, 2018·Current Treatment Options in Oncology·Thomas A Ollila, Adam J Olszewski
Jul 22, 2021·Leukemia & Lymphoma·Urshila Durani, Stephen M Ansell
Nov 20, 2021·Journal of Cutaneous Pathology·Jack LeeAlejandro A Gru

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.